Listing 1 - 2 of 2 |
Sort by
|
Choose an application
Surgical and medical oncologists have been unable to decrease renal cell carcinoma mortality for uncertain reasons, although a lot of progress has been made in diagnosis and imaging, recognition of different genetic and pathological entities, management of localized disease and in the research on new drug treatments for advanced stages of the disease, potentially combined with surgery. The purpose of this book, which tackles a number of separate interesting topics, is to provide further insight into the disease and the management of early and advanced renal cell carcinoma. The volume is divided into different parts; the first part covers the characterization of renal masses and the second part covers rare distinct pathological entity. In the management section, active surveillance, partial nephrectomy and radiofrequency ablation are presented. A separate chapter reviews the management of Von Hippel Lindau disease, and finally, conventional and aberrant signaling pathways are explored.
Oncology. --- Carcinoma, Renal Cell. --- Tumors --- Adenocarcinoma Of Kidney --- Adenocarcinoma, Renal --- Chromophil Renal Cell Carcinoma --- Chromophobe Renal Cell Carcinoma --- Clear Cell Renal Carcinoma --- Clear Cell Renal Cell Carcinoma --- Collecting Duct Carcinoma --- Collecting Duct Carcinoma (Kidney) --- Collecting Duct Carcinoma of the Kidney --- Nephroid Carcinoma --- Papillary Renal Cell Carcinoma --- Renal Cell Cancer --- Renal Cell Carcinoma --- Renal Cell Carcinoma, Papillary --- Renal Collecting Duct Carcinoma --- Sarcomatoid Renal Cell Carcinoma --- Adenocarcinoma, Renal Cell --- Carcinoma, Hypernephroid --- Grawitz Tumor --- Hypernephroma --- Renal Carcinoma --- Adenocarcinoma Of Kidneys --- Adenocarcinomas, Renal Cell --- Cancer, Renal Cell --- Carcinoma, Collecting Duct --- Carcinoma, Collecting Duct (Kidney) --- Carcinoma, Nephroid --- Carcinoma, Renal --- Carcinomas, Collecting Duct --- Carcinomas, Collecting Duct (Kidney) --- Carcinomas, Renal Cell --- Collecting Duct Carcinomas --- Collecting Duct Carcinomas (Kidney) --- Hypernephroid Carcinoma --- Hypernephroid Carcinomas --- Hypernephromas --- Kidney, Adenocarcinoma Of --- Nephroid Carcinomas --- Renal Adenocarcinoma --- Renal Adenocarcinomas --- Renal Carcinomas --- Renal Cell Adenocarcinoma --- Renal Cell Adenocarcinomas --- Renal Cell Cancers --- Renal Cell Carcinomas --- Tumor, Grawitz --- Oncology
Choose an application
This is the fourth Special Issue in Pharmaceuticals within the last six years dealing with aspects of radiopharmaceutical sciences. It demonstrates the significant interest and increasing relevance to ameliorate nuclear medicine imaging with PET or SPECT, and also radiotherapeutical procedures.Numerous targets and mechanisms have been identified and have been under investigation over the previous years, covering many fields of medical and clinical research. This development is well illustrated by the articles in the present issue, including 13 original research papers and one review, covering a broad range of actual research topics in the field of radiopharmaceutical sciences.
n/a --- pretargeting --- radioiodination --- neurodegeneration --- phosphoramidon --- GRPR --- molecular imaging --- allosteric modulator --- radiosynthesis --- separation --- ?-CIT. --- PET/CT imaging --- technetium-99m --- gastrin-releasing peptide receptor --- metabotropic glutamate receptor subtype 5 --- glutamate --- oncogenic fusions --- Fusarinine C --- hypoxia --- tirapazamine (TPZ) --- 68Ga --- sentinel lymph node --- 99mTc-radioligand --- iodine-131 --- electrophilic radioiodination --- 4-dioxide (BTDO) --- minigastrin --- ceftriaxone --- tropomyosin receptor kinase --- carbonic anhydrase IX --- ABP688 --- NPY(Y1)R --- MMPEP --- radiosensitizer --- neprilysin-inhibition --- radiochemistry --- girentuximab --- benzotriazine-1 --- gallium-68 --- cholecystokinin-2 receptor --- tumor targeting --- radioimmunotherapy --- salivary gland uptake --- metabolic stability --- tumor hypoxia --- multimerization --- oxidizing agent --- neuroinflammation --- gastrin-releasing peptide --- dextran --- carbon-11 --- peptide heterodimers --- apparent molar activity --- radiometals --- microglia --- rituximab --- [18F]FMISO --- [11C]meta-hydroxyephedrine --- Iodo-Gen® --- mannose --- 177Lu-radiopharmaceuticals --- azomycin nucleosides --- breast cancer --- click chemistry --- small animal imaging --- SR 4317 --- benzotriazine-1-monoxide (BTMO) --- bombesin --- prostate cancer --- Chloramine T --- 99mTc-radiopharmaceuticals --- ketamine --- PSMA-617 --- positron emission tomography --- hydrazinonicotinic acid (HYNIC) --- renal cell carcinomas --- [18F]PSS232 --- PET --- endoradiotherapy
Listing 1 - 2 of 2 |
Sort by
|